Compare Ascendis Pharma A/S (ASND) vs Bank of Nova Scotia (BNS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Bank of Nova Scotia — how do they compare? Ascendis Pharma A/S trades at $257.5 (market cap $16.67B), while Bank of Nova Scotia trades at $89.03 (market cap $108.32B). The key difference: Bank of Nova Scotia is far larger — about 6.5× Ascendis Pharma A/S's market cap, and Bank of Nova Scotia pays a 3.64% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | BNS | |
|---|---|---|
Market Cap | $16.67B | $108.32B |
Sector | Health | Financials |
52-Week High | $277.18 | $90.29 |
52-Week Low | $189.74 | $56.41 |
Enterprise Value | $17.04B | — |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
Bank of Nova Scotia (BNS) trades at $90.34, up 2.01% with a bullish technical outlook supported by moving averages. The bank has delivered three consecutive earnings beats, with Q2 2026 EPS expected at $1.53. Recent acquisition of MapleMark Bank and dividend increase to $1.14 demonstrate strategic growth initiatives. Valuation metrics show P/E of 17.1 and P/B of 1.96, while maintaining strong profitability with 24.86% net income margin.
BNS presents a compelling investment case with strong fundamentals and analyst support (52.63% buy ratings), though revenue growth has been modest and interest expenses remain elevated. The stock faces risks from economic uncertainty and credit quality concerns, but dividend stability and improving ROE to 11.87% provide downside protection. Upside potential exists if the bank maintains earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →
